Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

First Subject Enrolled in Phase II/III Study of Eisai's Anti-mtbr Tau Antibody E2814 for Dominantly Inherited Alzheimer's Disease (Diad), Conducted by DIAN-TUTOKYO, Jan 19, 2022 - (JCN Newswire) - Eisai

Related Keywords

Tabeta ,Mie ,Japan ,Tokyo , ,University College London ,Investor Relations Department ,National Institutes Of Health ,National Institute On ,Drug Administration ,Alzheimer Network ,Washington University School Of Medicine ,Eisai Co Ltd ,Alzheimer Network Trials Unit ,Public Relations Department ,Alzheimer Clinical Trial Consortium ,Eisai Inc Us Libby Holman ,Subject Enrolled ,Dominantly Inherited Alzheimer ,Washington University School ,Tau Nexgen ,Dominantly Inherited Alzheimer Network ,Inherited Alzheimer ,University College ,Clinical Trial Consortium ,National Institute ,National Institutes ,Biologics License Application ,Breakthrough Therapy ,Disease Assessment Scale Cognitive ,Clinical Dementia Rating ,State Examination ,Relations Department ,Libby Holman ,Eisai ,Anti ,Amyloid ,Meta ,Rotofibril ,Ntibody ,Lecanemab ,Elected ,Background ,Therapy ,Nexgen ,Study ,